Table 1

Effects of moxonidine treatment on metabolic parameters in SHRs and SHROBs

SHRsSHROBs
ControlMoxonidineControlMoxonidine
Body weight (g)325  ± 31314  ± 35623  ± 271-a 563  ± 321-b
Mean blood pressure (mm Hg)144  ± 4125  ± 101-b 125  ± 4102  ± 101-b
Urine protein (mg/24 h)45  ± 940  ± 12283  ± 701-a 121  ± 301-b
Urinary epinephrine (μg/24 h)0.33  ± 0.080.20  ± 0.100.42  ± 0.090.17  ± 0.061-b
Urinary norepinephrine (μg/24 h)1.17  ± 0.101.37  ± 0.591.72  ± 0.161-a 0.79  ± 0.351-b
Blood glucose (mg/dl)47  ± 648  ± 954  ± 452  ± 2
Plasma insulin (ng/ml)0.4  ± 0.10.5  ± 0.116.8  ± 5.41-a 4.8  ± 1.21-b
Insulin/glucose ratio0.01  ± 0.0020.01  ± 0.0040.50  ± 0.111-a 0.10  ± 0.021-b
Free fatty acids (mM)1.56  ± 0.071.29  ± 0.121-b 2.36  ± 0.211-a 1.78  ± 0.231-b

  • Data are means ± S.E.M. n = 18 for both SHR and SHROB control groups, and n = 4–7 for both SHRs and SHROBs treated with moxonidine, except for catecholamines in SHR animals (n = 2).

  • ↵1-a Significantly different from SHR control, P< .05.

  • ↵1-b Significantly different from control, P < 0.05.